Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (31-40 of 157) with videos related to

Pageof 16
Sort By:
Clinical Pharmacology and Therapeutics|January 24, 2025
Effect of Target-Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic FunctionElise Burmeister Getz, Richard R Stein, Martin Fink, et al.
Journal of Clinical Gastroenterology|March 14, 2020
Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver DiseaseAmandeep Singh, Falgun Gosai, Mohamed T Siddiqui, et al.
Antiviral Research|January 25, 2011
Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapyEric Lawitz, Eliot Godofsky, Regine Rouzier, et al.
World Journal of Hepatology|November 22, 2019
Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohortGeorge Khoudari, Amandeep Singh, Mazen Noureddin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 30, 2018
Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertibZobair M Younossi, Maria Stepanova, Eric Lawitz, et al.
Plos One|August 31, 2018
Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosisNaim Alkhouri, Casey Johnson, Leon Adams, et al.
Journal of Hepatology|June 24, 2023
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver diseaseManuel Romero-Gómez, Eric Lawitz, R Ravi Shankar, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 10, 2013
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis CZobair M Younossi, Maria Stepanova, Linda Henry, et al.
Plos One|October 5, 2018
Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosisNaim Alkhouri, Casey Johnson, Leon Adams, et al.
Gastro Hep Advances|June 15, 2026
Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation SystemNaim Alkhouri, Raj Vuppalanchi, Mazen Noureddin, et al.
Pageof 16

Showing results (31-40 of 157) with videos related to

Sort By:
Pageof 16
Clinical Pharmacology and Therapeutics|January 24, 2025
Effect of Target-Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic FunctionElise Burmeister Getz, Richard R Stein, Martin Fink, et al.
Journal of Clinical Gastroenterology|March 14, 2020
Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver DiseaseAmandeep Singh, Falgun Gosai, Mohamed T Siddiqui, et al.
Antiviral Research|January 25, 2011
Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapyEric Lawitz, Eliot Godofsky, Regine Rouzier, et al.
World Journal of Hepatology|November 22, 2019
Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohortGeorge Khoudari, Amandeep Singh, Mazen Noureddin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 30, 2018
Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertibZobair M Younossi, Maria Stepanova, Eric Lawitz, et al.
Plos One|August 31, 2018
Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosisNaim Alkhouri, Casey Johnson, Leon Adams, et al.
Journal of Hepatology|June 24, 2023
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver diseaseManuel Romero-Gómez, Eric Lawitz, R Ravi Shankar, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 10, 2013
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis CZobair M Younossi, Maria Stepanova, Linda Henry, et al.
Plos One|October 5, 2018
Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosisNaim Alkhouri, Casey Johnson, Leon Adams, et al.
Gastro Hep Advances|June 15, 2026
Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation SystemNaim Alkhouri, Raj Vuppalanchi, Mazen Noureddin, et al.
Pageof 16